Dr. Rosenthal is Professor of Microbiology & Immunology, as well as Director of MS and Certificate programs in Biohazardous Threat agents & Emerging Infectious Diseases

Summary:

• Ph.D., Kansas State University, 1969
• At Georgetown Since: 1975
• Current lab has capacity for both Ph.D. students and Post Doctoral Fellows
• Contact: (202) 687-1140; rosenthl@georgetown.edu

Details:

Dr. Rosenthal is an AIDS/cancer researcher who has focused on the association of herpesviruses with human cancer and AIDS. In September, 2002, Dr. Rosenthal, along with Dr. Lucey, co-organized the first GU/MedStar Workshop on Bioterrorism attended by over 500 students. Drs. Rosenthal and Lucey have previously co-organized a biodefense program as part of the Mini Medical School series for faculty, staff, and students and the community at large. Dr. Rosenthal is Director of the MS program in Biohazardous Threat Agents & Emerging Infectious Diseases as well as Director of the Online Certificate program in Biohazardous Threat Agents & Emerging Infectious Diseases and Co-Director of the resident certificate program in Biodefense & Public Policy.

Publications:

1) Rosenthal, L.J. and Doniger, J. 1994. The AIDS/Cancer Link: HCMV and HHV -6 genes associated with transformation or transactivation of HIV -1. JAMA, Southeast Asia 10: 131-135.

2) Araujo, J.C., Doniger, J., Kashanchi, F., Hermonat, P.L., Thompson, J., and Rosenthal, L.J. 1995 Human herpesvirus 6A ts suppresses both transformation by H-ras and transcription by the H-ras and human immunodeficiency virus type 1 promoters. J. Virol. 69:4933-4940.

3) Muralidhar, S., Doniger, J., Mendelson, E., Araujo, J.C., Kashanchi, F., Azumi, N., Brady, J.N., and Rosenthal, L.J. 1996. Human cytomegalovirus mtr11 oncoprotein binds to p53 and down-regulates p53-activated transcription. J. Virol. 70:8691-8700.

4) Kashanchi, F., Araujo, J., Doniger, J., Muralidhar, S., Khleif, S., Mendelson, E., Thompson, J., Azumi, N., Brady, J., Luppi, M., Torelli, G., and Rosenthal, L.J. 1997. Human herpesvirus type 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53. Oncogene 14: 359- 367.

5) Araujo, J.C., Doniger, J., Stoppler, H., Sadaie, M.R., and Rosenthal, L.J. 1997. Cell lines containing and expressing the human herpesvirus 6A ts gene are protected from both H-ras and BPV-1 transformation. Oncogene 14:937-943.

6) Muralidhar, S., Pumfery, A.M., Hassani, M., Sadaie, M.R., Kishishita, M., Brady, J.N., Doniger, J., Medveczky, P., and Rosenthal, L.J. 1998. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J. Virol. 72:4980-4988.

7) Doniger, J., Muralidhar, S., and Rosenthal, L.J. 1999. Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Clin. Microbiol. Rev. 12:367-382.

8) Muralidhar, S., and Rosenthal L.J. 1999. The hunt for a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) oncogene. Rec. Res. Devel. Virol. 1:873-890.

9) Muralidhar, S., Veystmann, G., Chandran, B., Ablashi, D., Doniger, J., and Rosenthal, L.J. 2000. Characterization of the human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) oncogene, Kaposin (ORFK12). J. Clin. Virol. 16:203-213.

10)Curreli, F., Cerimele, F., Muralidhar,S., Rosenthal, L.J., Cesarman, E., Friedman-Kien, A , Flore, O., 2002.Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi?s sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic replication. J. Virol, 6:5308-5219.

11) Ifon, E., Pang,A., Johnson,W., Cashman, K., Zimmerman,S., Muralidhar, S., Chan, W-Y., Casey, J., and Rosenthal,L. 2004. Cancer Cell International C. Research Support "Characterization of KSHV (HHV -8) Kaposin Oncogene" Principal Investigator: Leonard J. Rosenthal, Ph.D.

Medline publications list